Glaukos and Santen have entered a new license agreement for the development and commercialization of the PreserFlo microshunt, replacing the previous agreements between the companies, according to a press release.
The agreement grants Glaukos commercialization rights for the microshunt in the United States, Australia, New Zealand, Canada, Brazil, Mexico and the rest of Latin America, the release said. Additionally, Glaukos receives control of all development activities for the microshunt in those territories, as well as all clinical development and regulatory duties in the United States after